Baker Ellis Asset Management LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 1.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,500 shares of the insurance provider’s stock after selling 40 shares during the period. Baker Ellis Asset Management LLC’s holdings in Humana were worth $602,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in HUM. Independent Portfolio Consultants Inc. increased its stake in Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after buying an additional 94 shares in the last quarter. Guardian Life Insurance Co. of America boosted its position in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the last quarter. Point72 Asia Hong Kong Ltd bought a new position in shares of Humana during the first quarter valued at about $128,000. Westbourne Investment Advisors Inc. bought a new position in shares of Humana during the second quarter valued at about $205,000. Finally, Hengehold Capital Management LLC bought a new position in shares of Humana during the second quarter valued at about $209,000. Hedge funds and other institutional investors own 99.13% of the company’s stock.
Humana Inc. (NYSE:HUM) traded down 0.15% during mid-day trading on Friday, hitting $247.28. The company had a trading volume of 754,398 shares. The company has a market capitalization of $35.74 billion, a price-to-earnings ratio of 20.34 and a beta of 0.91. The firm’s 50 day moving average is $241.05 and its 200 day moving average is $224.57. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $255.27.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The business had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the previous year, the business earned $2.30 earnings per share. On average, equities research analysts predict that Humana Inc. will post $11.55 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.65%. Humana’s payout ratio is 13.06%.
ILLEGAL ACTIVITY WARNING: “Humana Inc. (NYSE:HUM) Position Decreased by Baker Ellis Asset Management LLC” was originally posted by BNB Daily and is the property of of BNB Daily. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/humana-inc-nysehum-shares-sold-by-baker-ellis-asset-management-llc-updated.html.
Several brokerages recently issued reports on HUM. UBS AG reaffirmed a “neutral” rating and set a $237.00 target price (up previously from $205.00) on shares of Humana in a research report on Wednesday, June 28th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $223.00 target price (up previously from $200.00) on shares of Humana in a research report on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $257.00 target price on shares of Humana in a research report on Friday, August 4th. Morgan Stanley lifted their target price on Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $244.35.
In other news, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at $3,421,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the sale, the vice president now directly owns 8,150 shares in the company, valued at $1,890,474. The disclosure for this sale can be found here. Insiders sold 41,406 shares of company stock worth $10,355,086 over the last ninety days. Insiders own 0.80% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.